celecoxib has been researched along with Epidermolysis Bullosa Dystrophica in 1 studies
Epidermolysis Bullosa Dystrophica: Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reimer, A | 1 |
| Lu, S | 1 |
| He, Y | 1 |
| Bruckner-Tuderman, L | 1 |
| Technau-Hafsi, K | 1 |
| Meiss, F | 1 |
| Has, C | 1 |
| von Bubnoff, D | 1 |
1 other study available for celecoxib and Epidermolysis Bullosa Dystrophica
| Article | Year |
|---|---|
Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; C | 2020 |